Navigation Links
Chugai in Medical News

Roche Diabetes Care Announces Unique Coaching Program for Diabetes Educators as Part of Long-Term Commitment to Fight the Disease

... Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in chugai Pharmaceutical, Japan. For more information: www.roche-diagnostics.us . All trademarks used or mentioned in this release are protected by law....

Global Autoimmune Disease Therapeutics Market to Reach $50 Billion by 2015, According to a New Report by Global Industry Analysts

...ce is characterized by participants such as Abbott Laboratories, Amgen Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bristol-Myers Squibb Company, chugai Pharmaceutical Co., Ltd., Elan Corporation, plc, Eli Lilly And Company, F. Hoffmann-La Roche AG, Genentech, Inc., GlaxoSmithKline plc, Johnson & J...

ACTEMRA(R) (tocilizumab) Studies to be Featured at the European League Against Rheumatism (EULAR) Congress

...ates. ACTEMRA is part of a co-development agreement between Roche and chugai Pharmaceutical Co. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional in...

Roche Announces New Co-pay Program in Pennsylvania that Makes It Easier for Patients with Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips

... Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in chugai Pharmaceutical, Japan. For more information: www.roche-diagnostics.us . All trademarks used or mentioned in this release are protected by law....

Roche Announces New Co-pay Program in Florida that Makes It Easier for Patients with Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips

... Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in chugai Pharmaceutical, Japan. For more information: www.roche-diagnostics.us . All trademarks used or mentioned in this release are protected by law....

Roche Announces New Co-Pay Program in California That Makes it Easier for Patients With Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips

... Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in chugai Pharmaceutical, Japan. For more information: www.roche-diagnostics.us . All trademarks used or mentioned in this release are protected by law....

Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology

...e pharmacokinetics and significant reduction in viral load, with good tolerability and safety.(3) Romark recently entered into an agreement granting chugai Pharmaceutical Co., Ltd., a member of the Roche Group, an exclusive license to develop and market nitazoxanide for the treatment of chronic hepatitis ...

Growth Opportunities for Actemra Will Propel Roche to Sixth Position in the Rheumatoid Arthritis Market by 2012

...lines of biological therapy, and reserve agents with other mechanisms of action, such as Orencia and Biogen Idec/Genentech's Rituxan (also marketed by chugai and Zenyaku Kogyo in Japan, and marketed as MabThera in Europe by Roche), largely for TNF-alpha inadequate responders. According to the new report ent...

Global Growth Factors (Blood and Tissue) Market to Reach $52.1 Billion by 2012, According to New Report by Global Industry Analysts

...rtho Inc, Lonza Group, Maxygen Inc, Merck Serono International SA, NsGene A/S, PeproTech Inc, Rentschler Biotechnologie GmbH, F Hoffmann-La Roche Ltd, chugai Pharmaceutical Co Ltd, Genentech Inc, Shantha Biotechnics, Scil Proteins GmbH, and Wockhardt Ltd, among others. The report titled "Growth Fac...

FDA Advisory Committee Recommends Approval of ACTEMRA(R) (tocilizumab) for the Treatment of Rheumatoid Arthritis

...n the United States and Europe. ACTEMRA is part of a co-development agreement with Chugai, a Japanese company. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and syste...
Chugai in Medical Technology

Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients

...DA). ACTEMRA is part of a co-development agreement between Roche and chugai Pharmaceutical Co. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional in...

Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer

... Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in chugai Pharmaceutical, Japan. For more information: http://www.roche.com . All trademarks used or mentioned in this release are protected by law. ...

Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients

...ates. ACTEMRA is part of a co-development agreement between Roche and chugai Pharmaceutical Co. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional in...

Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)

.... ACTEMRA is part of a co-development agreement between Roche and chugai Pharmaceutical Co. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional in...

New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients

...d States and Europe. ACTEMRA is part of a co-development agreement between Roche and Chugai Pharmaceutical Co. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and syste...

ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments

...d States and Europe. ACTEMRA is part of a co-development agreement between Roche and Chugai Pharmaceutical Co. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and syste...

ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies

...n the United States and Europe. ACTEMRA is part of a co-development agreement with Chugai, a Japanese company. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and syste...

New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients

... the United States and Europe. ACTEMRA is part of a co-development agreement with Chugai, a Japanese company. In April 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, ACTEMRA was approved for the treatment of rheumatoid arthritis, juvenile idiopathic arth...

International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet

...n the United States and Europe. ACTEMRA is part of a co-development agreement with Chugai, a Japanese company. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2006, additional indications for rheumatoid arthritis and systemic-onset juvenile idiopathic a...

Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis

...bition of structural damage in 2008. ACTEMRA is part of a co-development agreement with Chugai, a Japanese company. ACTEMRA was launched in Japan by chugai in June 2005 as a therapy for Castleman's disease. Additional indications for RA and systemic-onset juvenile idiopathic arthritis were also filed in J...
Chugai in Biological Technology

Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan

Chugai Pharmaceutical Gains Rights to Develop and Market Nitazoxanide for the Treatment of Chronic Hepatitis C TAMPA, Fla., Feb. 17 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, and Chugai Pharmaceutical Co. Ltd., a member of the Roche Group, today announced...

Roche Announces Back-to-Basics Approach to Diabetes Care - Simpler is Better

... Group posted sales of 45.6 billion Swiss francs. Genentech (United States) is a wholly owned member of the Roche Group. Roche has a majority stake in chugai Pharmaceutical (Japan). For more information, visit www.roche-diagnostics.us . All trademarks used or mentioned in this release are protected ...

Roche Announces Long-Term Commitment to Tackle Growing Epidemic of Diabetes

... Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in chugai Pharmaceutical, Japan. For more information: www.roche-diagnostics.us . All trademarks used or mentioned in this release are protected by law....

Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer

...nald served as Senior Vice President and Chief Business Officer at Aeterna Zentaris, and, prior to that, Senior Vice President, Business Operations at chugai Pharma USA. At both firms, she had a key role in establishing new directions for the enterprise and facilitating relationships with the financial com...

ACTEMRA(R) (tocilizumab) Studies to be Featured at American College of Rheumatology Annual Scientific Meeting

...in the United States and Europe. ACTEMRA is part of a co-development agreement with Chugai Pharmaceuticals Co. In June 2005, ACTEMRA was launched by chugai in Japan as a therapy for Castleman's disease; in April 2008, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and syste...

David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO

...f experience in the pharmaceutical industry, most recently as President and CEO of AEterna Zentaris. Dr. Mazzo also has served as President and CEO of chugai Pharma USA, LLC, the U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan, a member of the Roche Group. Dr. Mazzo replaces Regado co- founder D...

Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development

... on their product development platforms. Prior to joining Chiltern International, Ms. Wood served as the Director, Product Development for Oncology at chugai Pharma USA in San Diego. "We are pleased to welcome Diana to Stason," said Mr. Fan. "As a seasoned business development executive, she has built a h...

Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...BELLO A/S (OMX Nordic Exchange Copenhagen: ALK.B) chugai PHARM CO (Tokyo SE: 4519) DR REDDYS LABS LTD (NYS...) Add ABRAXIS BIOSCIENCE INC (NASDAQ: ABII ) chugai PHARM CO (Tokyo SE: 4519) DR REDDYS LABS LTD (NYS...N ) CARL ZEISS MEDITEC (Frankfurt, Germany: AFX) chugai PHARM CO (Tokyo SE: 4519) CIGNA CORP (NYSE: CI )...

Leading global Big Pharma companies of 2005

... +21% 30 32 Altana (Germany) $2.8 +27% Source: Pharmaceutical Executive , May 2006 * includes sales from acquisition of Japanese company chugai but does not include sales from majority-owned position in Genentech ** merger of Yamanouchi and Fujisawa to become Astellas *** does not include re...
Other Tags
(Date:4/18/2014)... turns 160 years of neuroanatomy on its head. , ... essential for the fast transmission of impulses along the ... thought, according to a new work lead by Professor ... and the University,s Department of Stem Cell and Regenerative ... Department of Molecular and Cellular Biology. , "Myelin is ...
(Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at Virginia ... blocking a particular molecule in metastatic breast cancer reduces ... of lung metastases. BRI scientists have found in models ... tumors by 60 - 80 percent and can keep ... The $1.8 million five-year grant comes from the National ...
(Date:4/18/2014)... . A ... A team led by Ludwik Leibler from the Laboratoire ... Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits Paris ... principle of adhesion by aqueous solutions of nanoparticles can ... tissues. This easy-to-use gluing method has been tested on ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2
(Date:4/17/2014)... New Rochelle, NY, April 17, 2014The development of stem ... on the ability to characterize stem cell populations based ... Cross have discovered a new marker that is highly ... human umbilical cord blood, which they describe in an ... journal from Mary Ann Liebert, Inc., publishers. The article ...
(Date:4/17/2014)... Marc Andr Gauthier and Professor Luca Razzari of ... been awarded large grants from the John R. ... Innovation (CFI) for the acquisition of state-of-the-art biotech ... added matching grants from the Ministre de l,Enseignement ... de la Technologie (MESRST). These new laboratories will ...
(Date:4/17/2014)... German . ... also provide us with a continuous stream of information about ... sit still in a car the world glides by ... Seemingly without effort, our brain calculates self-motion from this "optic ... a steady gaze during our own movements. Together with biologists ...
Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4
Other Contents